Pinatuzumab vedotin (INN;[1] development codes DCDT2980S and FCU2703) is a monoclonal antibody designed for the treatment of B-cell malignancies.

[2] This drug was developed by Genentech/Roche.

[citation needed] This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.